The announcement of Phase 3 study results is a critical event for biopharmaceutical companies, often leading to significant stock price movements. Positive results can lead to increased investor confidence and potential regulatory approval, while negative results can have the opposite effect. Given the specificity of the announcement and its importance to LENZ Therapeutics' product pipeline, this event is highly relevant and important to the company's valuation.